Relief Therapeutics 报告了罕见、痛苦的大疱性表皮松解症的新治疗方案的积极结果。 Relief Therapeutics reports positive results for a new treatment option for the rare, painful epidermolysis bullosa.

Relief Therapeutics 宣布了 RLF-TD011 治疗大疱性表皮松解症的临床试验的积极最终结果，大疱性表皮松解症是一种罕见的皮肤病，会导致严重的水泡和皮肤脆弱。 Relief Therapeutics has announced positive final results from a clinical trial of RLF-TD011 for treating epidermolysis bullosa, a rare skin condition that causes severe blisters and skin fragility. 试验显示了有希望的结果,有可能为患有这种痛苦和衰弱疾病的病人提供一种新的治疗选择。 The trial showed promising outcomes, potentially offering a new treatment option for patients suffering from this painful and debilitating disease.